Skip to main content
. 2018 Sep 17;8(9):e021779. doi: 10.1136/bmjopen-2018-021779

Table 1.

Characteristics of included studies

Study
(first author, year)
Additional sources Country Year started Design Aim Population N (FSWs) at baseline Age (median)† Current contraceptive use‡ (%) Consistent condom use§ Number of sex partners/frequency of sex¶ Gender-based violence (GBV)/alcohol/other risk factor HIV/STI prevalence
Outcome 1: unintended pregnancy
 Behets,39 2005 Madagascar 2004 Prospective cohort (with intervention). Assess acceptability and feasibility of diaphragm use. FSWs who use condoms inconsistently. 91 28 Any: 47%
LARC or permanent: <1%.
0% with clients in last month (inconsistent use was an inclusion criterion). Five partners.
Six sex acts.
N/A. Vaginitis/Pelvic inflammatory disease (PID): 8%.
TP (RPR): 27%.
 Behets,40 2008 Author††
Khan et al 4
Penman-Aguilar et al 72
Madagascar 2005 RCT (pilot). Assess acceptability and feasibility of diaphragm and microbicide use for STI prevention. Women with high-risk sex behaviours (sex work self-reported: 81% current, 100% ever). 192 29 Any (excl. condoms): 24%. 0% in last 2 weeks (inconsistent use was an inclusion criterion). Six casual partners.
10 sex acts.
Ever violence from casual partner for suggesting condom: 21%.
Ever received more money for no condom: 38%.
N/A.
 Braunstein,32 2011 Braunstein et al 73 Rwanda 2006 Prospective cohort. Measure HIV incidence
(secondary aim: measure pregnancy incidence).
HIV-uninfected women at high risk of HIV exposure (94% reported current sex work). 397 24 Any: 91%.
LARC or permanent: 0%.
21% with clients
18% with non-paying partners.
90 partners in past 3 months.
10 clients per week.
40 vaginal sex acts in last month.
Forced sex ever: 19%.
Alcohol before sex: 52%.
CT: 5%.
GN: 12%.
TV: 17%.
TP (RPR+TPHA pos): 7%.
HSV2: 54%.
 Chersich,34 2014 Author††
Luchters et al 5
Kenya (Mombasa). 2006 Prospective cohort. Assess HIV incidence and microbicide trial feasibility.
This substudy: investigate links between alcohol use, and unsafe sex and incident HIV infection.
HIV-uninfected FSWs. 386 Mean 25.1 Any (incl. consistent condom use): 57.1%.
LARC: 3.0%.
Permanent: 0%.
21.3% in last 3 months. N/A. Hazardous or harmful drinking: 26.8%.
Ever had abortion: 21%.
N/A.
 Deschamps,33 2016 Deschamps et al 74 Haiti, Puerto Rico and Dominican Republic 2009 Prospective cohort. Assess feasibility of establishing a high-risk cohort for HIV vaccine trials.
This substudy: assess retention, HIV and pregnancy incidence and risk behaviours.
HIV-uninfected FSWs. 634 24‡‡ Permanent: 10.0% (excluded from pregnancy analysis).
Others not reported.
0.5% in last 6 months. 447 partners in last 6 months‡‡. Forced sex by client in last 6 months: 37.1%.
Heavy drinker: 38.8%.
Drug use: 14.0%.
N/A.
Gaffoor,42 2013 Author††
Skoler-Karpoff et al 75
South Africa (one site of a multisite trial) 2004 RCT (phase 3, double blind, placebo-controlled). Test safety and efficacy of the microbicide. Carraguard for HIV prevention.
This substudy: describe prevalence and associations of forced sex.
HIV-uninfected sexuallyactive women (3% FSWs). 41 §§ §§ N/A. §§ N/A. §§
  Lara,41 2009 Author†† Dominican Republic 2006 Prospective cohort (with intervention). Assess acceptability of the female condom and diaphragm, determinants of use, and impact on unprotected sex. FSWs. 243 58.8% aged 20–29 years Any (excl. condoms): 22.2%.
Permanent: 0%.
66% in last month. N/A. Ever had abortion: 70%. HIV: 1%.
CT: 13%.
GN: 2%.
TP (VDRL): 8%.
 McClelland,45 2008 Author††
Martin et al 76
McClelland et al 77
McClelland et al 78
Kenya (Mombasa) 2003 RCT (placebo-controlled, nested in an open cohort study). Test efficacy of monthly periodic presumptive antibiotic treatment at reducing incidence of vaginal infections and promoting vaginal Lactobacillus colonisation. HIV-uninfected FSWs. 310 32 Any (excl. condoms): 35.5%.
LARC: 3.6%.
Permanent: 2.9%.
Median 100% coverage of sex acts in past week.‡‡ One partner.
One sex act.‡‡
N/A. GN: 0.3%.
TV: 1%.
Cervicitis (microscopy): 0.6%.
HSV2: 74%.
BV: 34.5%.
 Peterson,46 2007 Author††
Macqueen et al 66
Ghana, Cameroon and Nigeria 2004 RCT (phase 2, double blind, placebo controlled). Investigate safety and preliminary effectiveness of tenofovir disoproxil fumarate in preventing HIV infection. HIV-uninfected women who work in hotels, bars, markets in high HIV transmission areas (areas known for sex work). 936 Mean 23.6‡‡ Any (excl. condoms): 7.22%.
LARC: <2%.
Permanent: <2%.
N/A. Mean 21 partners in 30 days.
Mean 12 coital acts per week.
N/A. Any STI in last 6 months (self-reported): 41.2%.
 Watson-Jones,44 2008 Author††
Odutola et al 79
Tanzania 2004 RCT (double blind, placebo controlled). Determine whether HSV2 suppressive therapy reduces the risk of HIV acquisition and genital shedding of HIV. Female workers at food and recreational facilities at risk of HIV (38% FSWs). 499 §§ §§ §§ §§ §§ §§
Outcome 2: pregnancy (intention undefined)
 Bazzi,54 2015 Author††
Syvertsen et al 80
Mexico 2010 Prospective cohort. Identify time varying risk factors for STI acquisition within FSWs’ intimate partnerships. FSWs with drug use history and their steady male partners. 212 33 Any (excl. condoms): 53.3%.
LARC: 12.3%.
Permanent: 25.5%.
Often or always: 56%. N/A. In last year:
physical assault by partner: 41%.
Sexual coercion in relationship: 9%.
In last 6 months:
hazardous drinking: 23%.
Intravenous drug use: 62%.
HIV: 2.6%.
CT: 5.9%.
GN: 1.2%.
TP (active): 1.4%.
Any STI: 8%.
 Page,38 2013 Author††
Duff et al 55
Couture et al 81
Cambodia 2009 Prospective cohort. Estimate HIV and STI prevalence, incidence and associated factors.
This substudy: describe contraceptive utilisation and correlates of incident pregnancy.
Young women who practice SW and/or have multiple partners (all those recruited had practiced SW). 220 60.3% aged 25–29 years Any hormonal (not LARC): 10.8%.
LARC: <1.0%.
N/A. Four partners in last month. In last year: physical or sexual violence by client: 26.0%.
Intimate partner: 20.1%.
In last 3 months:
stimulant drug use: 27.0%.
Abortion: 11.3%.
HIV: 16.2%.
 Feldblum,35 2007 Feldblum et al 57
Hoke et al 82
Madagascar 2001 RCT. Assess impact of two condom promotion interventions.
This substudy: estimate pregnancy incidence rate and predictive factors.
FSWs. 935 Mean 28.3 Any highly effective (excl. condoms): 16.3%. No unprotected sex with any partners: 13.2%. Mean 5–6 partners. N/A. CT: 14.6%.
GN: 21.7%.
TV: 11.7%.
Any STI: 36.1%.
‡‡
 Kaewkungwal,36 2013 Rerks-Ngarm et al 83 Thailand (two provinces) 2003 RCT (multisite double blind placebo controlled). Assess the efficacy of two vaccines to prevent HIV.
This substudy: determine the qualities and outcomes of women’s participation.
HIV-uninfected women (5% FSWs). 318 N/A N/A. §§ N/A. §§ N/A.
 Kaul,47 2004 Yadav et al 84
Fonck et al 85
Kenya (Nairobi) 1998 RCT (double blind placebo controlled). Assess impact of monthly PPT on HIV and STI incidence. HIV-uninfected FSWs. 430 28.6‡‡ Any hormonal (not LARCs): 39.1%. 17.2% with casual partner.‡‡ 15.4 partners.‡‡ Daily alcohol: 47.6%.
Ever intravenous drug use: 4.1%.
CT: 9.9%.
GN: 10.3%.
TV: 12.2%.
TP: 4.4%.
HSV2: 73.9%.
BV: 51.1%.
 Liu,53 2015 Author†† China 2009 Cluster RCT. Assess the impact of a preventive intervention for FSWs on condom use with clients and partners. FSWs. 750 Mean 27.8‡‡ LARC: 29.9%. 43.6% in past month. Mean 8.3 clients.‡‡ N/A. CT: 14.0%.
GN: 3.3%.
TP: 1.3%.
Any STI: 16.9%.
 McClelland,37 2011 Author††
Martin et al 76
McClelland
et al 86
Kenya (Mombasa) 1993 Open cohort. Assess HIV-1 incidence and relationships between hormonal contraception, STIs and HIV.
This substudy: examine relationship between risk behaviour and biologic outcomes (STI, pregnancy, seminal fluid deposition) among HIV-positive FSWs.
HIV-infected FSWs. 898 31 Any (excl. condoms): 43.0%.
LARC: 2.34%.
Permanent: 2.67%.
55% in past week. One partner.
Two sex acts.
N/A. N/A.
 Price,49 2012 Author†† Kenya (Nairobi, Kilifi) 2005 Prospective cohort. Describe populations at risk of HIV, including HIV incidence, in preparation for HIV trials. HIV-uninfected women and men at risk of HIV (75% of women were FSWs). 515 §§ N/A. N/A. N/A. §§ Any non-ulcerative STI: 9.1%.
Genital ulcers: 1.5%.
TP: 0.6%.
Any STI: 10.6%.
 Priddy,56 2011 Kenya (Nairobi) 2008 Prospective cohort. Assess HIV risk behaviour and incidence, STI prevalence, vaginal practices and retention. HIV-uninfected FSWs. 200 Mean 28 Any non-barrier method: 52.0%.
LARC: 3.0%.
Permanent: 1.0%.
N/A (only reported sometimes/always use). Mean per day:
2.4 regular clients.
1.9 casual clients.
Sexual/physical violence related to Sex work (SW) in last month: 19.5%.
Sometimes/always paid more for no condom: 29.0%.
Sometimes/always has sex while intoxicated: 31.5%.
CT: 5.5%.
GN: 6.0%.
TV: 9.0%.
TP: 2.5%.
HSV2 (antibody): 72.0%.
BV: 38.0%.
 Robb,51 2016 Author††
Rono et al 87
Kenya, Tanzania and Uganda 2009 Prospective cohort. Describe the trajectory of acute HIV infection. HIV-uninfected women and men at high risk for HIV (64% FSWs). 1463 N/A Any hormonal (incl. implant): 36.5%.
IUD: 0.5%.
Permanent: 0.5%.
32.6% with clients.
20.3% with non-paying partners.
N/A. Abortion in last 3 months: 0.43%. N/A.
 Strathdee,43 2013 Author††
Vera et al 88
Gaines et al 89
Mexico 2008 RCT (four-arm factorial). Determine effectiveness of two behavioural interventions to reduce sexual and injecting risk. HIV-uninfected FSWs who inject drugs. 584 33 Any (excl. condoms): 39.3%.
LARC: 25.3%.
Permanent: 17.8%.
14.9% with regular clients.
11.7% with casual clients.
30 clients per month.
51 paid sex acts per month.
N/A. CT: 12.0%.
GN: 2.2%.
TV: 33.6%.
TP (active): 8.4%.
 Van Damme,48 2002 Author††
Vandebosch
et al 90
Ramjee
et al 91
Benin, Cote d’Ivoire, South Africa and Thailand 1996 RCT (multisite triple blind placebo-controlled; open cohort design). Determine effectiveness of nonoxynol-9 microbicide in prevention of HIV-1. HIV-uninfected FSWs. 892 26 N/A. N/A (only reported use of condom in ≥50% of sex acts). Three partners per day. N/A. CT: 4.4%.
GN: 5.1%.
TV: 3.5%.
TP: 11.2%.
 van Loggerenberg,52 2008 Author††
Naicker
et al 92
South Africa (Durban) 2004 Prospective cohort. Understand HIV-1 subtype C acquisition, pathogenesis and disease progression.
This substudy: describe cohort characteristics and HIV-incidence rates, and report challenges in establishing and maintaining the cohort.
HIV-uninfected women who practice SW (79%) and/or have multiple partners. 193 Mean 34.3 N/A. 53.9% with casual partners.
20.4% with steady partners.
Two partners per week. N/A. Any STI (CT, GN, TV, MG, TP, HSV2): 31.3%.
 Vandepitte,93 2013 Author††
Vandepitte
et al 94
Uganda (urban slum). 2008 Prospective cohort. Understand dynamics of HIV and STI infections among FSWs.
This substudy: investigate patterns of clearance and recurrence of untreated Mycoplasma genitalium infection.
FSWs. 1027 Mean 26 N/A. 59.8% in last month. At least daily sex for money: 50.5%. Problem drinking: 55.7%. MG: 14%.
 Vielot,50 2015 Author†† Kenya (Nairobi) 2009 Prospective cohort. Compare the duration of high risk HPV infection among FSWs by exposure to STIs, using a highly sensitive biomarker assay. FSWs. 350 28 LARC: 15.5%.
Permanent: 2.1%.
Most of the time/always:
73.8% with clients.
24.6% with non-paying partners.
10 partners per week. N/A. HIV: 24.0%.
CT: 3.8%.
GN: 2.3%.
TV: 7.3%.
MG: 12.8%.

†Median unless specified.

‡Any=modern contraceptive method including condoms, unless specified; LARC=long-acting reversible contraception (implants or IUDs); Permanent=any method of permanent contraception, for example, tubal ligation or hysterectomy.

§Always uses condoms (unless specified).

¶Median number per week unless specified. Sex partners may be paying, non-paying, regular or casual, unless specified.

††‘Author’ indicates additional data were obtained from the author. Other references listed here reported on the same study and were used for data extraction.

‡‡Reported results segregated by sub-group; data presented here are overall estimates.

§§Not disaggregated by sex work status.

BV, bacterial vaginosis; CT, Chlamydia trachomatis; FSW, female sex worker; HSV2, herpes simplex virus type 2; MG, Mycoplasma genitalium; N/A, not measured or reported, data not available from author; NG, Neisseria  gonorrhoeae; RCT, randomised controlled trial; STI, sexually transmitted infection; TP, Treponema pallidum (syphilis); TV, Trichomonas vaginalis.